← Browse by Condition
Medical Condition

malignant neoplasm

Total Trials
9
Recruiting Now
9
Trial Phases
Phase 2, Phase 3, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for malignant neoplasm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — malignant neoplasm Clinical Trials

How many clinical trials are currently recruiting for malignant neoplasm?
ClinicalMetric currently tracks 9 actively recruiting clinical trials for malignant neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for malignant neoplasm?
malignant neoplasm research spans Phase 1 (3 trials), Phase 2 (4 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a malignant neoplasm clinical trial?
Eligibility criteria for malignant neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
4
Phase 3
1
Top Sponsors
Merck Sharp & Dohme LLC 3 trials
Cancer Research UK 1 trial
Rutgers, The State University of New Jersey 1 trial
First Affiliated Hospital of Fujian Medical University 1 trial
Zhongnan Hospital 1 trial

Recruiting Clinical Trials

NCT05770037 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
View Trial →
NCT07252739 Phase 2
Recruiting
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Enrollment
140 pts
Location
United States, Chile...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT02688517
Recruiting
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
Enrollment
1,100 pts
Location
United States
Sponsor
Rutgers, The State University ...
View Trial →
NCT07630974 Phase 1, Phase 2
Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Enrollment
134 pts
Location
United States, Austr...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT06438250 EARLY_Phase 1
Recruiting
68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies
Enrollment
5 pts
Location
China
Sponsor
First Affiliated Hospital of F...
View Trial →
NCT05034146
Recruiting
68Ga-FAPI PET/CT in Malignant Tumors
Enrollment
500 pts
Location
China
Sponsor
Zhongnan Hospital
View Trial →
NCT06051760 Phase 1
Recruiting
NV-001 in the Treatment of Advanced Solid Tumors
Enrollment
20 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT07785609 Phase 2
Recruiting
A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)
Enrollment
200 pts
Location
United States, Hong ...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT04453072
Recruiting
A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant
Enrollment
20 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C...
View Trial →

Related Conditions

haematological malignancy (1) lymphoproliferative disorders (1) neoplasms by histologic type (1) neoplasms by site (1) cancer (1) anaplastic large cell lymphoma (1) lymphoma (1) renal cell carcinoma (1) neuroblastoma (1) solid tumour (1) fibroblast activation protein inhibitor (1) pet ct (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology